N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=7 Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Acceptability of patientMpower Platform From Patient & Healthcare Professional Perspective — 3; 1; 1; 4 Participants
N/A N=204 OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
Idiopathic Pulmonary Fibrosis
Primary: Idiopathic Pulmonary Fibrosis (IPF)-Related Costs — 38923.57; 22613.68; 20369.94; 37183.17 Euro (€) — p=0.0002
N/A N=178 A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
Idiopathic Pulmonary Fibrosis · Interstitial Lung Disease
Primary: Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home…
Phase 3 N=180 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement) — 9; 6 participants — p=0.39
Phase 3 N=555 Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52 — 16.5; 31.8; 22.7; 9.7 percentage of patients
Phase 2 N=147 A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks — -77.70; 2.72; -95.62; 6.10 Milliliter
Phase 3 N=113 Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months — 11.407; 14.583 percent change
N/A N=209 IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With IPF Symptoms — 88.0; 51.8; 49.4; 42.9 Percentage of participants
Phase 3 N=1,177 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 — -183.48; -138.60; -114.65 Milliliters (mL) — p=0.0222
Phase 2 N=71 Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
Primary: Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE) — 13; 15; 15; 12 Participants
N/A N=101 Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
Pulmonary Fibrosis
Primary: Annual Change From Baseline in Percentage of Predicted Forced Vital Capacity (FVC) at Week 52 — -0.5; 4.1 Percentage of predicted FVC — p=0.505
N/A N=58 Treatment of IPF With Laparoscopic Anti-Reflux Surgery
Idiopathic Pulmonary Fibrosis · Gastroesophageal Reflux
Primary: Forced Vital Capacity (FVC) — -0.13; -0.05 liters
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
Phase 3 N=551 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks. — -207.32; -113.59 mL/year — p=0.0002
N/A N=1,798 Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
Idiopathic Pulmonary Fibrosis
Primary: Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis (IPF) Patients — 781; 202; 190; 255 Participants
Phase 3 N=1,058 Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With Adverse Events — 98.0 percentage of participants
Phase 3 N=515 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -239.91; -114.65 mL/year — p=<0.0001
Phase 3 N=236 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Pulmonary Fibrosis
Primary: Overall Change in Forced Vital Capacity — -0.18; -0.19 liters
Phase 2 N=23 Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients With Treatment-Emergent Adverse Events (AEs) — 4; 11 Participants
Phase 2 N=6 A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Effect of Gefapixant on BP — 122; 76 units on a scale
Phase 3 N=60 Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline to Week 26 in Absolute Millilitre (mL) Forced Vital Capacity (FVC) — 128.78 Milliliter (mL)
N/A N=1,798 Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: Total All-cause Medical Costs — 12647.73; 13580.61; 17549.74; 15375.10 United States dollars — p=0.516
Phase 2 N=68 A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline in Forced Vital Capacity (FVC) at Week 26 — 2865.43; 2817.08; -31.29; -79.47 mL — p=0.495
Phase 2 N=29 Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Alveolitis, Fibrosing · Fibrosis, Pulmonary · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Test — -26; -7 meters
Phase 2 N=177 Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline…
Phase 3 N=435 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity (FVC) — -8.0; -10.0; -12.4 Change in Percent Predicted FVC
Phase 2 N=9 Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
IPF
Primary: Number of Participants With Respiratory and/or Hemodynamic Deteriorations — 1; 3 Participants
N/A N=34,960 Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
Lung Diseases, Interstitial
Primary: Incidence Probability of Progression to Pulmonary Fibrosing-Interstitial Lung Disease (PF-ILDs) — 0.147; 0.249; 0.334; 0.395 Cumulative incidence probability
Phase 3 N=344 Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity(FVC) — -9; -10 Change in Percent Predicted FVC